FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to pharmaceutical compositions for the combined therapy of arthropathies, except for rheumatoid arthritis, degenerative disk diseases, joint pains and/or autoimmune disease (particularly alopecia, neurodermitis). There are presented: a pharmaceutical composition for the above application containing a glucocorticoid, exosomes prepared of autologous blood and a cytokine antagonist ortokin or anakinra; a method for producing it involving the pharmaceutical composition containing the exosomes prepared of autologous blood and the cytokine antagonist ortokin or anakinra, and the pharmaceutical composition containing the glucocorticoid and the cytokine antagonist ortokin or anakinra, and versions of using the above substances for producing the pharmaceutical composition for the combined therapy.
EFFECT: technical effect consists in achieving the synergetic effect both on the exposure rate and remote outcomes of the specified diseases with reducing side effects of the glucocorticoid (cortisone).
33 cl, 1 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION PREPARATIONS WITH CYTOKINE ANTAGONIST AND CORTICOSTEROID | 2010 |
|
RU2526161C2 |
| AGONISTS AND ANTAGONISTS OF HYBRID IL-1 RECEPTOR OF I TYPE | 2011 |
|
RU2754957C2 |
| METHODS OF TREATMENT OR PREVENTION OF ASTHMA THROUGH ADMINISTRATION OF IL-4R ANTAGONIST | 2013 |
|
RU2801531C2 |
| THERAPEUTIC PRODUCT CONTAINING IL-33 ANTAGONIST FOR THE TREATMENT OF ENDOMETRIOSIS | 2018 |
|
RU2791705C2 |
| PEPTIDE, OBTAINED FROM MPHOSPH1, AND INCLUDING ITS VACCINE | 2016 |
|
RU2731099C2 |
| PEPTIDE DERIVED FROM FOXM1, AND INCLUDING ITS VACCINE | 2016 |
|
RU2738418C2 |
| NOVEL PROTEIN CONJUGATE AND USE THEREOF FOR PREVENTING OR TREATING NON-ALCOHOLIC STEATOHEPATITIS, OBESITY AND DIABETES | 2021 |
|
RU2822001C1 |
| ACTIVATED POLYPEPTIDES OF INTERLEUKIN 12 AND METHODS OF USE THEREOF | 2019 |
|
RU2826183C2 |
| ACTIVATED POLYPEPTIDES OF INTERLEUKIN-2 AND METHODS OF USE THEREOF | 2019 |
|
RU2826454C2 |
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
